Want to see ELAN full AI Analyst Report?
ELAN Stock Chart & Stats
$25.41
$0.50(2.01%)
At close: 4:00 PM EDT
$25.41
$0.50(2.01%)
Day’s Range― - ―
52-Week Range$16.89 - $27.98
Previous CloseN/A
Volume2.71M
Average Volume (3M)4.49M
Market Cap
$11.05B
Enterprise Value$15.84K
Total Cash (Recent Filing)$530.00M
Total Debt (Recent Filing)$3.92B
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Nov 10, 2026EPS Estimate
0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding499,621,830
10 Day Avg. Volume4,451,939
30 Day Avg. Volume4,494,459
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.72
Price to Sales (P/S)2.38
P/FCF Ratio39.55
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$31.30Price Target Upside23.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)1.12
Revenue Forecast (FY)$5.12B
Bulls Say, Bears Say
Bulls Say
Sustained Organic Revenue GrowthConsistent organic growth and raised full‑year guidance reflect durable end‑market demand across pet and farm segments. Higher volumes and modest pricing indicate franchise strength that supports reinvestment, margin expansion, and a clearer path to converting top‑line gains into sustained earnings over the next several quarters.
Strong New Product Commercial TractionHigh clinic penetration, strong reorder rates and meaningful first‑line adoption signal durable product–market fit for Zenrelia. This drives repeatable innovation revenue, supports premium pricing and channel relationships, and increases the odds that innovation revenue targets are sustainable contributors to growth over the medium term.
Solid Cash Generation And Improving LeveragePositive operating and free cash flow while earnings remain challenged demonstrates robust cash conversion and financial flexibility. Declining net leverage and a clear year‑end net leverage target reduce refinancing risk, enabling continued product investment and debt reduction without immediate reliance on external equity over the next 2–6 months.
Bears Say
Bottom‑line Profitability Still NegativeDespite revenue and gross margin improvements, persistent negative net margins and negative ROE indicate the company has not yet converted operating gains into sustainable bottom‑line profitability. This limits capacity to deliver returns to shareholders and increases reliance on continued margin improvement and cash flow to derisk the business.
Manufacturing/Supply Ramp Risk (Befrena)A constrained ramp for a high‑demand mAb launch delays revenue capture and margin benefits from Befrena. Bioreactor scaling and phased supply create multi‑quarter execution risk that can postpone payback on R&D and marketing investments and limit sustainable innovation revenue growth in the near term.
Elevated Operating Expenses For Launches/DTCSustained double‑digit OpEx growth to fund launches and direct‑to‑consumer initiatives increases operating leverage pressure. If revenue and margin gains from these investments are slower or smaller than planned, elevated expenses could slow the company’s path to net profitability and limit near‑term cash flow improvement.
Elanco Animal Health News
ELAN FAQ
What was Elanco Animal Health’s price range in the past 12 months?
Elanco Animal Health lowest stock price was $16.89 and its highest was $27.98 in the past 12 months.
What is Elanco Animal Health’s market cap?
Elanco Animal Health’s market cap is $11.05B.
When is Elanco Animal Health’s upcoming earnings report date?
Elanco Animal Health’s upcoming earnings report date is Nov 10, 2026 which is in 91 days.
How were Elanco Animal Health’s earnings last quarter?
Elanco Animal Health released its earnings results on Aug 05, 2026. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.269 by $0.071.
Is Elanco Animal Health overvalued?
According to Wall Street analysts Elanco Animal Health’s price is currently Undervalued.
Does Elanco Animal Health pay dividends?
Elanco Animal Health does not currently pay dividends.
What is Elanco Animal Health’s EPS estimate?
Elanco Animal Health’s EPS estimate is 0.2.
How many shares outstanding does Elanco Animal Health have?
Elanco Animal Health has 499,621,830 shares outstanding.
What happened to Elanco Animal Health’s price movement after its last earnings report?
Elanco Animal Health reported an EPS of $0.34 in its last earnings report, beating expectations of $0.269. Following the earnings report the stock price went up 2.422%.
Which hedge fund is a major shareholder of Elanco Animal Health?
Currently, no hedge funds are holding shares in ELAN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elanco Animal Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.30 (23.18% Upside)
$31.30 (23.18% Upside)
Blogger Sentiment
Bullish
ELAN Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 11.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $533.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.32%
Trailing 12-Months
Company Description
Elanco Animal Health
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
ELAN Company Deck
ELAN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive: strong top-line performance (8% organic growth, $1.368B revenue), robust innovation momentum (Zenrelia, Credelio Quattro, AdTab), margin expansion (adjusted gross margin +80 bps, adjusted EBITDA +21%, adjusted EPS +31%), raised full-year guidance, and improving leverage (target ~3.0x year-end). Near-term headwinds include inventory cost pressures, elevated inflation, continued operating expense investments (DTC/R&D) and some regional/timing softness in International Farm Animal. Supply constraints for Befrena and moderating comparisons for some Farm Animal products are acknowledged but framed as manageable. Overall, highlights materially outweigh the limited lowlights.View all ELAN earnings summariesELAN Stock 12 Month Forecast
Average Price Target
$31.30
▲(23.18% Upside)
Technical Analysis
Ownership Overview
1.00% Insiders
51.31% Mutual Funds
4.87% Other Institutional Investors
21.39% Public Companies and
Individual Investors